Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Crescita Therapeutics Inc
(TSX:
CTX
)
0.6400
UNCHANGED
Streaming Delayed Price
Updated: 9:36 AM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crescita Therapeutics Inc
< Previous
1
2
Next >
Crescita Reports Second Quarter 2024 Results
August 07, 2024
From
Crescita Therapeutics
Via
Business Wire
Crescita Secures Contract Manufacturing Revenue of $US10 Million Over 4 Years
July 22, 2024
From
Crescita Therapeutics
Via
Business Wire
Leading Canadian Healthcare Services Provider Selects Crescita as Exclusive Manufacturing Partner under 5-Year Agreement
July 19, 2024
From
Crescita Therapeutics
Via
Business Wire
Crescita Expands Medical Aesthetic Portfolio with MicronJetTM600 The World’s Smallest Intradermal Delivery Device
July 17, 2024
From
Crescita Therapeutics
Via
Business Wire
Crescita Completes Acquisition of Strategic Assets of Occy Laboratory
June 26, 2024
From
Crescita Therapeutics
Via
Business Wire
Crescita to Acquire Strategic Assets of Occy Laboratory
June 20, 2024
From
Crescita Therapeutics
Via
Business Wire
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
June 06, 2024
From
Crescita Therapeutics
Via
Business Wire
Crescita Reports First Quarter 2024 Results
May 08, 2024
From
Crescita Therapeutics
Via
Business Wire
Crescita Reports Q4 and Fiscal 2023 Results
March 13, 2024
From
Crescita Therapeutics
Via
Business Wire
Crescita Reports Third Quarter 2023 Results
November 08, 2023
From
Crescita Therapeutics Inc.
Via
Business Wire
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
August 29, 2023
From
Crescita Therapeutics
Via
Business Wire
Crescita Reports Second Quarter 2023 Results
August 09, 2023
From
Crescita Therapeutics
Via
Business Wire
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
June 21, 2023
From
Crescita Therapeutics
Via
Business Wire
Crescita Reports First Quarter 2023 Results
May 11, 2023
From
Crescita Therapeutics Inc.
Via
Business Wire
Crescita Reports Q4 and Fiscal 2022 Results
March 15, 2023
From
Crescita Therapeutics Inc.
Via
Business Wire
Crescita Reports Third Quarter 2022 Results
November 09, 2022
From
Crescita Therapeutics Inc.
Via
Business Wire
Crescita Reports Second Quarter 2022 Results
August 10, 2022
From
Crescita Therapeutics Inc.
Via
Business Wire
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
May 12, 2022
From
Crescita Therapeutics
Via
Business Wire
Crescita Reports First Quarter 2022 Results
May 11, 2022
From
Crescita Therapeutics
Via
Business Wire
Crescita to Present at Bloom Burton & Co. Healthcare Investor Conference
April 21, 2022
From
Crescita Therapeutics
Via
Business Wire
Crescita Reports Q4 and Fiscal 2021 Results
March 23, 2022
From
Crescita Therapeutics Inc.
Via
Business Wire
Crescita Therapeutics Announces Renewal of Normal Course Issuer Bid
December 15, 2021
From
Crescita Therapeutics
Via
Business Wire
Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®
December 13, 2021
From
Crescita Therapeutics
Via
Business Wire
Crescita Reports Third Quarter 2021 Results and Appoints New Board Member
November 11, 2021
From
Crescita Therapeutics
Via
Business Wire
Crescita Announces Exclusive Canadian Distribution Agreement with Obagi Cosmeceuticals LLC
September 09, 2021
From
Crescita Therapeutics
Via
Business Wire
Crescita Acquires Minority Interest in The Best You®
September 07, 2021
From
Crescita Therapeutics Inc.
Via
Business Wire
Crescita Therapeutics and STADA Enter 15-Country Exclusive Licensing Agreement for Pliaglis®
August 18, 2021
From
Crescita Therapeutics Inc.
Via
Business Wire
Crescita Reports Second Quarter 2021 Results and Provides Corporate Update
August 11, 2021
From
Crescita Therapeutics
Via
Business Wire
Crescita Therapeutics Announces 9-Country Licensing Agreement with Croma Pharma for Pliaglis®
June 28, 2021
From
Crescita Therapeutics Inc.
Via
Business Wire
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
May 12, 2021
From
Crescita Therapeutics
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.